Kuros BiosciencesCSBTF 71 Graham Number is $1.55 as of Dec. 2025, which is 93% below its 10-year median of 22.34. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $46.45 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 399 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 99.5% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-05), the stock price of Kuros Biosciences is $22.72. Kuros Biosciences's graham number for the quarter that ended in Dec. 2025 was $1.55. Therefore, Kuros Biosciences's Price to Graham Number ratio for today is 14.70.
The historical rank and industry rank for Kuros Biosciences's Graham Number or its related term are showing as below:
CSBTF'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 15.54 Med: 22.34 Max: 22.34
Current: 15.56
During the past 13 years, the highest Price to Graham Number ratio of Kuros Biosciences was 22.34. The lowest was 15.54. And the median was 22.34.
CSBTF's Price-to-Graham-Number is ranked worse than 99.5% of 399
companies
in the Medical Devices & Instruments industry
Industry Median: 1.83
vs CSBTF: 15.56
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Kuros Biosciences (OTCPK:CSBTF) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Kuros Biosciences's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Dec. 2025 )
=
22.72
/
1.55
=
14.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Kuros Biosciences Graham Number Related Terms
Kuros Biosciences Graham Number Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Price-to-Graham-Number vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a Graham Number of $1.55 as of Dec. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on Kuros Biosciences and its competitors. This is 93% below median its historical median of 22.34. Over the past decade, Kuros Biosciences' Graham Number has ranged from 15.54 to 22.34. According to the industry distribution chart, Kuros Biosciences ranks #397 out of 399 companies in the Medical Devices & Instruments industry, placing it in the top 99.5%.
Is Kuros Biosciences' Graham Number too high?
Kuros Biosciences' current Graham Number of $1.55 is 93% below median its 10-year median of 22.34. Over the past 10 years, this metric has ranged from a low of 15.54 to a high of 22.34. The Medical Devices & Instruments industry median Graham Number is 1.83. Kuros Biosciences' value of $1.55 is 15.3% below this industry median. Based on the distribution chart, Kuros Biosciences ranks #397 out of 399 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Graham Number compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #397 out of 399 companies for Graham Number. This places Kuros Biosciences in the lower half of its industry. The industry median Graham Number is 1.83. Kuros Biosciences' value of $1.55 is 15.3% below this benchmark. Historically, Kuros Biosciences' own Graham Number has ranged from 15.54 to 22.34 over the past decade. While the company's 10-year median is 22.34 vs. the industry median of 1.83, Kuros Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Medical Devices & Instruments company?
The median Graham Number among Medical Devices & Instruments companies is 1.83, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Graham Number of $1.55 is 15.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Graham Number is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Graham Number is $1.55, which is 93% below median its own 10-year median of 22.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $46.45, compared to a current price of $22.72 — trading 51.1% below its estimated fair value. The current Graham Number is $1.55, which is 93% below median its 10-year median of 22.34 and 15.3% below the Medical Devices & Instruments industry median of 1.83. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Graham Number is $1.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 51.1% below its estimated GF Value™ of $46.45.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Graham Number: $1.55 (93% below median its 10-year median of 22.34)
GF Value™: $46.45 vs. price of $22.72 (51.1% below fair value)
Industry Position: 15.3% below the Medical Devices & Instruments median (#397 of 399)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
